EssilorLuxottica : Good resistance for the first quarter with revenue down 10%, Taking measures to control costs and preserve cash & Preparing for recovery and delivering on our responsibilities to all

NEXT STORY
Demant A/S: Interim Management Statement covering the period year-to-date
PREV STORY
BLOCKCHAINARMY FOUNDER PRESIDENT INVITES GOVERNMENTS FOR A COOPERATION ON PANDEMIC
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Euroepan Point-of-Care, Biosensors & Mobile Diagnostics Conference 2019: Testing Landscape, Novel Technologies & Regulatory Approval – Rotterdam, Netherlands – June 18th-19th, 2019

author_avatar
NASDAQ Market News

Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial

CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology ...

author_avatar
NASDAQ Market News

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

author_avatar
NASDAQ Market News